Argenica Therapeutics (ASX:AGN) Current Deferred Revenue: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
23 GF Score
Price A$0.17
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics Current Deferred Revenue?

Argenica Therapeutics ASX:AGN 23 Current Deferred Revenue is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:AGN with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Argenica Therapeutics's current deferred revenue for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Argenica Therapeutics Current Deferred Revenue Related Terms

Argenica Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics Current Deferred Revenue Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
0.00 0.00 0.66 0.70 0.62

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.70 0.00 0.62 0.00
ASX:AGN
23GF Score
Argenica Therapeutics Ltd ASX:AGN
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of A$0.00 Mil mean?
Argenica Therapeutics (ASX:AGN) has a Current Deferred Revenue of A$0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Argenica Therapeutics and its competitors.
Is Argenica Therapeutics' Current Deferred Revenue too high?
Argenica Therapeutics' current Current Deferred Revenue is A$0.00 Mil. Overall, Argenica Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' Current Deferred Revenue compare to VRTX and REGN?
Argenica Therapeutics' Current Deferred Revenue of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Argenica Therapeutics and its competitors. Argenica Therapeutics's current Current Deferred Revenue is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current Current Deferred Revenue of A$0.00 Mil. The current Current Deferred Revenue is A$0.00 Mil. Argenica Therapeutics' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current Current Deferred Revenue is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
23GF Score

Get the complete analysis for ASX:AGN

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.17
Price